ARVN

Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026.

Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.

Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.

Arvinas presented Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, showing dose-dependent improvements in oculomotor function and correlations between LRRK2 reduction and improvements in biomarkers related to endolysosomal function, neuroinflammation, and synaptic integrity in Parkinson's disease patients. The findings support continued clinical evaluation of ARV-102 for neurodegenerative diseases associated with LRRK2 dysregulation.

Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.

TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.

Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids.

The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.